The ARMYDA trials (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) at Campus Bio-Medico University: rationale, results and future horizons.
Myocardial protection by atorvastation pretreatment was found in several trials applied to percutaneous coronary intervention by the ARMYDA study group. This article reviews those studies and explores future avenues.
di Sciascio
Germano
G
Department of Cardiovascular Sciences, Campus Bio-Medico, University of Rome, Rome, Italy.
D000787:Angina Pectoris / Q000601:surgery; D017130:Angioplasty / Q000009:adverse effects*; D000069059:Atorvastatin; D009202:Cardiomyopathies / Q000209:etiology / Q000517:prevention & control*; D005544:Forecasting; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000639:trends; D016896:Treatment Outcome
D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin